urlscan.io logo urlscan.io
SecurityTrails logo

usermod99test.kanerism.top Open in urlscan Pro
188.114.96.3  Public Scan

Back to summary
URL: https://usermod99test.kanerism.top/
Submission: On July 27 via automatic, source certstream-suspicious — Scanned from NL

Form analysis 2 forms found in the DOM

GET https://www.iavi.org/

<form role="search" method="get" id="searchform" class="searchform" action="https://www.iavi.org/">
  <div>
    <label class="screen-reader-text" for="s">Search for:</label>
    <input type="text" value="" name="s" id="s">
    <input type="submit" id="searchsubmit" value="Search">
  </div>
</form>

Name: mc-embedded-subscribe-form — POST https://iavi.us7.list-manage.com/subscribe/post?u=65ad404c928bcb0edfd984a08&id=bfee2c6c82&f_id=00d0dce4f0

<form action="https://iavi.us7.list-manage.com/subscribe/post?u=65ad404c928bcb0edfd984a08&amp;id=bfee2c6c82&amp;f_id=00d0dce4f0" method="post" id="mc-embedded-subscribe-form" name="mc-embedded-subscribe-form" class="validate" target="_blank"
  novalidate="novalidate">
  <div id="mc_embed_signup_scroll">
    <h2>Subscribe</h2>
    <p>Use this form to receive updates on IAVI‘s work and the latest news from the field.</p>
    <div class="mc-field-group">
      <label for="mce-FNAME" class="mc-label-ghost">First Name</label>
      <input type="text" name="FNAME" class="required text" required="" id="mce-FNAME" value="" placeholder="First Name *" aria-required="true">
    </div>
    <div class="mc-field-group">
      <label for="mce-LNAME" class="mc-label-ghost">Last Name</label>
      <input type="text" name="LNAME" class="required text" id="mce-LNAME" value="" required="" placeholder="Last Name *" aria-required="true">
    </div>
    <div class="mc-field-group"><label for="mce-EMAIL" class="mc-label-ghost">E-mail Address</label><input type="email" name="EMAIL" class="required email" id="mce-EMAIL" value="" required="" placeholder="E-mail Address *" aria-required="true"></div>
    <div class="mc-field-group input-group">
      <h2>Subscription Type </h2>
      <ul>
        <li><input type="checkbox" name="group[80579][1]" id="mce-group[80579]-80579-0" value=""><label for="mce-group[80579]-80579-0">IAVI Updates<span>Periodic updates on recent advances in biomedical innovations, policy initiatives, funding
              updates, stories from the field, and IAVI’s Discovery Newsletter.</span></label></li>
        <li><input type="checkbox" name="group[80579][2]" id="mce-group[80579]-80579-1" value=""><label for="mce-group[80579]-80579-1">IAVI Report<span>A publication covering the latest scientific and policy research in the quest to develop vaccines,
              antibodies, and other biomedical innovations to combat the spread of HIV and other infectious diseases.</span></label></li>
      </ul>
    </div>
    <div id="mce-responses" class="clear">
      <div class="response" id="mce-error-response" style="display: none;"></div>
      <div class="response" id="mce-success-response" style="display: none;"></div>
    </div>
    <div aria-hidden="true" style="position: absolute; left: -5000px;"><label for="hidden-mc-element">by Mailchimp</label><input type="text" name="b_65ad404c928bcb0edfd984a08_bfee2c6c82" id="hidden-mc-element" tabindex="-1" value=""></div>
    <div class="clear"><input type="submit" name="subscribe" id="mc-embedded-subscribe" class="button button--primary" value="Subscribe"></div>
  </div>
</form>

Text Content

Manage Cookie Consent


To provide the best experiences, we use technologies like cookies to store
and/or access device information. Consenting to these technologies will allow us
to process data such as browsing behavior or unique IDs on this site. Not
consenting or withdrawing consent, may adversely affect certain features and
functions.
Functional Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose
of enabling the use of a specific service explicitly requested by the subscriber
or user, or for the sole purpose of carrying out the transmission of a
communication over an electronic communications network.
Preferences Preferences
The technical storage or access is necessary for the legitimate purpose of
storing preferences that are not requested by the subscriber or user.
Statistics Statistics
The technical storage or access that is used exclusively for statistical
purposes. The technical storage or access that is used exclusively for anonymous
statistical purposes. Without a subpoena, voluntary compliance on the part of
your Internet Service Provider, or additional records from a third party,
information stored or retrieved for this purpose alone cannot usually be used to
identify you.
Marketing Marketing
The technical storage or access is required to create user profiles to send
advertising, or to track the user on a website or across several websites for
similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about
these purposes

Accept Deny View preferences Save preferences View preferences
Cookie Policy {title} {title}
IAVI Skip to content
Menu Close
Back to Main Menu
 * Our Work
   * Research & Development
     * Discovery
     * Epidemiology
     * Clinical Development
     * Product Development 
     * Global Access
     * Advocacy & Community Engagement 
   * Health Areas
     * Pipeline
     * HIV Vaccines 
     * HIV Antibodies 
     * Tuberculosis
     * Emerging Infectious Diseases
 * About
   * About IAVI
     * About IAVI
     * Our Story
     * Careers
     * Diversity, Equity, & Inclusion
     * Financial Statements
     * Contact us
   * Regions
     * Africa
     * Europe
     * India
     * United States
   * Leadership
     * Board of Directors
     * Senior Leadership
   * Funders & Partners
     * Funders
     * Partnerships
 * Media & Resources
   * News & Press
     * Features
     * Press Releases
     * In The News
   * Digital Media
     * Videos
     * Podcasts
   * Resources
     * IAVI Report
     * Scientific Publications
     * Vaccine Literacy Library
     * Fact Sheets & Publications

Search
Close
Search for:
 * Quick Links
   * Our Work
   * Emerging Infectious Diseases
   * Pipeline
   * Senior Leadership
 * Trending Now
   * HIV Vaccines
   * HIV Antibodies
   * Tuberculosis


AFFORDABLE, ACCESSIBLE
VACCINES & ANTIBODIES

We are a nonprofit scientific research organization that develops vaccines and
antibodies for HIV, tuberculosis, and emerging infectious diseases.

About us


OUR APPROACH

--------------------------------------------------------------------------------

We take a full-circle approach to product development, from the grassroots level
to the lab to legislative bodies.


MISSION

--------------------------------------------------------------------------------

To translate scientific discoveries into affordable, globally accessible public
health solutions.


VISION

--------------------------------------------------------------------------------

A world where all people have equitable access to innovative vaccines and
therapeutics.




OUR HEALTH AREAS

 * HIV
 * Tuberculosis
 * Lassa fever
 * Marburg virus
 * Sudan Ebolavirus
 * COVID-19


HIV


THE CHALLENGE

HIV/AIDS remains one of the deadliest infectious diseases, with 1.3 million
people acquiring HIV in 2022. Given the complexities of HIV, traditional
approaches to vaccine development have so far failed to result in a vaccine that
provides protection against HIV. However, a vaccine is still needed to bring a
true end to the HIV pandemic. Source: UNAIDS


OUR SOLUTION

IAVI scientists and our collaborators are developing next-generation HIV
vaccines to address the challenges of HIV vaccine design. Together, we have
pioneered promising new vaccination strategies and the discovery of broadly
neutralizing antibodies (bnAbs) against HIV. IAVI and our partners are
developing HIV bnAbs to prevent HIV acquisition while we advance vaccine
candidates.


TUBERCULOSIS


THE CHALLENGE

Tuberculosis (TB) is the world’s leading infectious disease killer. In 2022,
10.6 million people fell ill with TB and 1.3 million people died of TB disease.
The only available TB vaccine is the century-old Bacille Calmette-Guérin, or
BCG. While this vaccine has efficacy in protecting against severe TB disease in
infants and young children, it is largely ineffective in adolescents and adults,
among whom most transmission and disease occurs. Source: WHO


OUR SOLUTION

IAVI works across our global hubs with a diverse network of partners to advance
the most promising TB vaccine candidates from discovery through clinical trials,
and eventually, to post-licensure access. Our work extends to policy and
advocacy initiatives that support TB vaccine development and access in regions
where new vaccines are needed most.


LASSA FEVER


THE CHALLENGE

Lassa fever is an acute viral hemorrhagic illness endemic to West Africa that
causes significant annual outbreaks of disease. Lassa fever is difficult to
diagnose, and surveillance data is limited. Current estimates range from 300,000
to 500,000 cases and 5,000 related deaths each year. No licensed vaccines for
Lassa fever exist. Source: WHO


OUR SOLUTION

IAVI is developing a single-dose vaccine candidate for Lassa that is based on a
recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar
to that underlying an approved Ebola Zaire virus vaccine. IAVI’s Lassa vaccine
candidate was well tolerated and immunogenic over a wide dose range in a Phase I
clinical study. IAVI also conducts Lassa epidemiological studies and modeling to
support future vaccine access.


MARBURG VIRUS


THE CHALLENGE

Marburg virus is a filovirus and the causative agent of Marburg virus disease
(MVD), which has a case fatality ratio of up to 88%. Marburg virus has the
capacity to cause outbreaks with high fatality rates and is a potential
bioterror threat. No vaccines or antiviral treatments are approved for MVD. A
Marburg vaccine is urgently needed to respond to future outbreaks. Source: WHO


OUR SOLUTION

IAVI is developing a vaccine candidate for Marburg that is based on a
recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar
to that underlying an approved Ebola Zaire virus vaccine, which is now approved
by the U.S. FDA and registered for use in several African countries. Preclinical
data demonstrates that IAVI’s Marburg vaccine candidate is highly protective in
an animal model with one dose.


SUDAN EBOLAVIRUS


THE CHALLENGE

Sudan ebolavirus is a filovirus and causes outbreaks of Ebola disease, most
recently in 2022 in Uganda. Case fatality rates of Ebola disease caused by Sudan
ebolavirus have varied from 41% to 100% in past outbreaks. The licensed vaccine
for Ebola Zaire virus does not provide cross protection against the Sudan
strain. An Ebola Sudan vaccine is urgently needed to prevent and respond to
future outbreaks. Source: WHO


OUR SOLUTION

IAVI is developing a vaccine candidate for Sudan ebolavirus that is based on a
recombinant vesicular stomatitis virus (rVSV) vector similar to the technology
underlying an approved Ebola Zaire virus vaccine. During the 2022 Ebola outbreak
in Uganda, the WHO selected IAVI’s Sudan ebolavirus vaccine candidate for a
planned ring vaccination trial. While the trial did not go forward due to
outbreak control, IAVI has continued clinical development to prepare for future
outbreaks.


COVID-19


THE CHALLENGE

Since December 2019, over 760 million cases of COVID-19 and 6.9 million deaths
have been recorded worldwide, but the actual number is thought to be higher.
While highly effective, approved COVID-19 vaccines do not fully block
transmission or breakthrough infection. Additional COVID-19 vaccines continue to
be an urgent need, particularly vaccines suitable for widespread use in middle
and low-income countries. Source: WHO


OUR SOLUTION

IAVI is developing a COVID-19 vaccine candidate that is based on a recombinant
vesicular stomatitis virus (rVSV) vector. The vaccine candidate has demonstrated
safety in humans when administered intramuscularly and has been produced at
scale to support larger future clinical trials. IAVI is also investigating an
intranasal formulation of our COVID-19 vaccine candidate to prevent infection.


OUR IMPACT

--------------------------------------------------------------------------------


WE CONDUCT PRECLINICAL AND CLINICAL TRIALS OF OUR OWN VACCINES AND ANTIBODIES.
OUR FOCUS IS ON DISEASES OF GLOBAL IMPORTANCE FOR WHICH THERE IS NO MARKET AND
LITTLE FINANCIAL INCENTIVE FOR DEVELOPMENT. WE ALSO COLLABORATE WITH AND SUPPORT
OTHER SCIENTIFIC ORGANIZATIONS TO CONDUCT THEIR OWN CLINICAL TRIALS OF PRIORITY
DISEASE PREVENTION AND THERAPEUTIC INTERVENTIONS.

--------------------------------------------------------------------------------

255 partners from academic, biotech, pharma sectors, civil society, and global
health initiatives

--------------------------------------------------------------------------------

53 biologics candidates supported by the IAVI Product Development Center, out of
which 25 advanced to clinical trials

--------------------------------------------------------------------------------

70,000 volunteers enrolled in observational epidemiology studies


OUR LOCATIONS



--------------------------------------------------------------------------------


IAVI AFRICA

 * Cape Town Office, South Africa
 * Nairobi Office, Kenya


IAVI EUROPE

 * Amsterdam Office, The Netherlands
 * Human Immunology Lab, London, U.K.


IAVI INDIA

 * Gurugram, Haryana Office
 * Antibody Translational Research Program, IAVI-THSTI, Faridabad


IAVI U.S.

 * New York Office
 * Vaccine Design & Development Lab, New York
 * Neutralizing Antibody Center, California


RECENT NEWS & MEDIA

Previous Next

IAVI Report


THE TIES THAT BIND

July 23, 2024
As thousands gather this week for the 25th International AIDS Conference in
Munich, Germany, participants will be looking for the threads that tie together
a quarter of a century of HIV/AIDS and the latest advances in treatment,
prevention, and cure research. Something critical to the progress in battling
this disease over the last 25 years […]
Read More

Features


LOOKING AHEAD TO ONE OF OUR BUSIEST WEEKS OF THE YEAR: IAVI AT THE INTERNATIONAL
AIDS CONFERENCE

July 15, 2024
IAVI is looking forward to a busy and exciting week at the International AIDS
conference, taking place July 22-26 in Munich, Germany. IAVI leaders will
participate in a range of sessions, including IAVI-organized satellite sessions,
posters, a pre-conference session, and, of course, many side meetings. Some
highlights of IAVI’s upcoming participation include: We welcome you […]
Read More

Features


IAVI SIGNS LEASE ON NEW VACCINE DESIGN AND DEVELOPMENT LAB IN JERSEY CITY, NJ

July 10, 2024
IAVI is pleased to announce that we have signed a lease on a new Vaccine Design
and Development Lab  (DDL) space in Jersey City, NJ. Construction has already
begun on the 29,782 sq. ft. space within a lab-ready life sciences building at
95 Greene Street and is slated for completion in early 2025. The DDL […]
Read More

Features


UNITAID, IAVI, MEDICINES PATENT POOL, AND WELLCOME PUBLISH NOVEL APPROACHES TO
ENABLE EQUITABLE ACCESS TO MONOCLONAL ANTIBODIES IN LOW- AND MIDDLE-INCOME
COUNTRIES

July 05, 2024
Unitaid, IAVI, the Medicines Patent Pool and Wellcome proudly announced the
publication of “Novel Approaches to Enable Equitable Access to Monoclonal
Antibodies in Low- and Middle-Income Countries” in PLoS Global Public Health. A
collaborative effort across IAVI’s lead author Shelly Malhotra, vice president
for global access and external affairs, and co-authors from partner
organizations, the article draws on a multistakeholder consultation, to address
critical barriers and proposes innovative strategies to enable equitable access
to monoclonal antibodies (mAbs) in low- and middle-in
Read More

Features


WORLD ZOONOSES DAY 2024: IAVI CELEBRATES PROGRESS IN LASSA VACCINE DEVELOPMENT

July 05, 2024
World Zoonoses Day is commemorated on July 6 and reminds us of the important
role human-animal interactions play in global health. It also commemorates the
first rabies vaccine given on July 6, 1885. “Zoonoses” is the collective term
for zoonotic, or animal-borne diseases. Some examples include the emerging
infectious diseases Ebola and Marburg, which are […]
Read More

Press Release


ADVANCING TOWARD A PREVENTATIVE HIV VACCINE

July 02, 2024
LA JOLLA, CA and NEW YORK, NY — July 2, 2024 — A major challenge in developing a
vaccine for HIV is that the virus mutates fast — very fast. Although a person
initially becomes infected with one or a few HIV strains, the virus replicates
and mutates quickly, resulting in a “swarm” of viral […]
Read More

The state of vaccine science now is far more powerful and sophisticated than it
has ever been. And I am confident that many of these challenges that we face
will be solved by vaccine development.

Mark Feinberg

President & CEO

We are a nonprofit scientific research organization that develops vaccines and
antibodies for HIV, tuberculosis, and emerging infectious diseases.

 * Instagram
 * YouTube
 * Facebook
 * LinkedIn


QUICK LINKS

--------------------------------------------------------------------------------

Careers

HIV Vaccines

HIV Antibodies

Tuberculosis

Emerging Infectious Diseases


CONTACT US

--------------------------------------------------------------------------------

IAVI U.S.
125 Broad Street, 9th Floor
New York, NY 10004
USAT: +1.212.847.1111
F: +1.212.847.1112



Contact us Diversity, Equity, & Inclusion Privacy Policy Terms of Use Compliance
& RFPs

©2024 International AIDS Vaccine Initiative. International AIDS Vaccine
Initiative®, IAVI®, and the IAVI logo® are registered trademarks of the
International AIDS Vaccine Initiative, Inc.


SUBSCRIBE

Use this form to receive updates on IAVI‘s work and the latest news from the
field.

First Name
Last Name
E-mail Address


SUBSCRIPTION TYPE

 * IAVI UpdatesPeriodic updates on recent advances in biomedical innovations,
   policy initiatives, funding updates, stories from the field, and IAVI’s
   Discovery Newsletter.
 * IAVI ReportA publication covering the latest scientific and policy research
   in the quest to develop vaccines, antibodies, and other biomedical
   innovations to combat the spread of HIV and other infectious diseases.


by Mailchimp

Manage consent